Vis enkel innførsel

dc.contributor.authorSiddiqui, Tahreem Ghazal
dc.contributor.authorCheng, Socheat
dc.contributor.authorGossop, Michael
dc.contributor.authorKristoffersen, Espen Saxhaug
dc.contributor.authorGrambaite, Ramune
dc.contributor.authorLundqvist, Christofer
dc.date.accessioned2020-08-04T08:00:14Z
dc.date.available2020-08-04T08:00:14Z
dc.date.issued2020-07-27
dc.description.abstract<i>Objectives</i> - Central nervous system depressants (CNSDs) such as opioids, benzodiazepine and Z-hypnotics are commonly used. However, CNSDs may influence cognitive function, especially in older hospitalised patients with comorbidities. The aim was to examine the association between CNSD use and cognitive function in older patients. We assessed global and domain specific cognitive function, among hospitalised older patients, including covariates for comorbidity, anxiety and depression.<p> <p><i>Design</i> - Cross-sectional hospital-based study.<p> <p><i>Settings</i> - Data was collected consecutively from inpatients at somatic wards of a general university hospital.<p> <p><i>Participants</i> - Older patients between 65 and 90 years with/without CNSD use for ≥4 weeks.<p> <p><i>Outcome measures</i> - The main outcome was cognitive function assessed by Cognistat. Secondary outcomes were routine clinical tests in the wards (mini-mental state examination (MMSE), trail making test (TMT) A and B, and clock drawing tests). Analyses were bivariate and multiple linear regression, adjusted for age, gender, and education. Covariates were comorbidity, depression and anxiety scores.<p> <p><i>Results</i> - The main result indicated that CNSD users (n=100) had (β=–3.4, 95% CI 6.27 to –0.58, p=0.017) lower Cognistat score than non-users (n=146), adjusted for age, gender, education, anxiety and depression, but not significant when including covariate for comorbidity (β= –2.50 - 5.45; –0.46, p=0.097). Comorbidity was associated with cognitive function (β=−0.77, 95% CI −1.22 to −0.14, p=0.014). Cognistat subdimensions associated with CNSD use were language (p=0.017) and calculation (p=0.003). In clock drawing test, users had lower scores than non-users (β=−0.80, 95% CI 1.24 to −0.36, p=0.004), but no significant difference was found with MMSE and TMT A or B. Z-hypnotics were associated with reduced cognitive function.<p> <p><i>Conclusion</i> - Among older hospitalised patients, global cognition and specific cognitive functions were associated with long-term use of CNSD medication as well as with somatic comorbidity.en_US
dc.descriptionSource at <a href=https://bmjopen.bmj.com/content/10/7/e038432.info>https://bmjopen.bmj.com/content/10/7/e038432.info</a>.
dc.identifier.citationCheng, Gossop, Kristoffersen, Grambaite, Lundqvist. Association between prescribed central nervous system depressant drugs, comorbidity and cognition among hospitalised older patients: a cross-sectional study. BMJ Open. 2020en_US
dc.identifier.cristinIDFRIDAID 1821052
dc.identifier.issn2044-6055
dc.identifier.urihttps://hdl.handle.net/10037/18906
dc.language.isoengen_US
dc.publisherBMJ Publishing Groupen_US
dc.relation.journalBMJ Open
dc.relation.projectIDinfo:eu-repo/grantAgreement/RCN/HELSEVEL-H/256431/Norway/HOW DO WE PROVIDE BETTER, SAFER AND MORE COST-EFFECTIVE CARE PATHWAYS FOR OLDER PEOPLE?//en_US
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2020 The Author(s)en_US
dc.subjectVDP::Medisinske Fag: 700en_US
dc.titleAssociation between prescribed central nervous system depressant drugs, comorbidity and cognition among hospitalised older patients: a cross-sectional studyen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel